Nautilus Biotechnology - NAUT Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares.
View NAUT analyst ratings or view top-rated stocks.

2 brokers have issued 12-month price objectives for Nautilus Biotechnology's stock. Their NAUT share price forecasts range from $2.00 to $6.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 66.0% from the stock's current price.
View analysts price targets for NAUT or view top-rated stocks among Wall Street analysts.

Nautilus Biotechnology's stock was trading at $1.80 at the start of the year. Since then, NAUT shares have increased by 33.9% and is now trading at $2.41.
View the best growth stocks for 2023 here.

Nautilus Biotechnology saw a decline in short interest in February. As of February 28th, there was short interest totaling 894,200 shares, a decline of 40.4% from the February 13th total of 1,500,000 shares. Based on an average trading volume of 138,400 shares, the short-interest ratio is presently 6.5 days. Approximately 1.8% of the shares of the company are short sold.
View Nautilus Biotechnology's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our NAUT earnings forecast.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its earnings results on Thursday, February, 23rd. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04.

Nautilus Biotechnology trades on the NASDAQ under the ticker symbol "NAUT."

Nautilus Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.77%), Clarius Group LLC (0.47%), Morgan Stanley (0.30%), Nantahala Capital Management LLC (0.23%), Sentinel Trust Co. LBA (0.15%) and Renaissance Technologies LLC (0.08%). Insiders that own company stock include Anna Mowry, Gwen E Weld, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, Subramanian Sankar and Sujal M Patel.
View institutional ownership trends.

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NAUT stock can currently be purchased for approximately $2.41.

Nautilus Biotechnology (NASDAQ:NAUT) has a market capitalization of $300.94 million. The company earns $-57,920,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

The company employs 113 workers across the globe.

Nautilus Biotechnology's mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.nautilus.bio. The company can be reached via phone at 206-333-2001 or via email at investorrelations@nautilus.bio.